Mark is a Managing Director at DC Advisory US. He brings nearly 20 years of experience to the firm, including over 60 completed M&A transactions and numerous equity and debt financings. Based in New York, he is a member of the firm’s Healthcare group, covering corporate clients in Healthcare Services, Life Sciences and Medical Devices, and Healthcare IT.

Mark has successfully advised corporate executives, boards of directors, founders/families, financial sponsors, and investors across the Healthcare Industry including ACOs, Ambulatory Surgery, Behavioral / Psychiatric Care, Biopharmaceutical and Life Sciences, Cancer Treatment, Care Management Organizations, Contract Research and Manufacturing Organizations, Dental Care and Supply, Drug Wholesaling & Distribution, GPOs, HCIT, Hospitals & Health Systems, Home Health, Managed Care / Health Insurance, Medical Devices, Medical Imaging, PBM, Pharmacy, Population Health, Rehabilitation, REITs, Revenue Cycle Management, Single- and Multi-Specialty Physician Practice Management, Skilled Nursing and Senior Living Facilities, Staffing, Tele-medicine and Vision sectors.

Before joining DCS Advisory, Mark served as Deputy Head of Hospitals & Health Systems M&A investment banking at Jefferies LLC. Previously, he served as a Director in the Global Mergers & Acquisitions Group of the investment banking division of Citigroup / Salomon Smith Barney, Inc. culminating in his role as Deputy Head of Middle Markets M&A. Other investment banking experience includes serving as a Senior Vice President in the Healthcare Investment Banking division of Ernst & Young Capital Advisors, LLC.

Mark has advised clients on corporate mergers, divestitures, acquisitions, joint ventures, equity and debt private and public capital raises, LBO and recapitalizations, contested M&A and defense, MOEs, going-private 13e-3s squeeze-outs, tracking stock, contingent consideration, M&A collars and forward purchase options, spinoffs and Reverse Morris Trusts, cross-border M&A, IRC §338(g) and 338(h)10 elections, and §382 NOL utilization. Mark has significant experience with public company mergers and tender offers.

He is a graduate of the University of Pennsylvania, having earned a B.S. in Economics (finance concentration) from The Wharton School of Business and a B.A. in Biochemistry from The College of Arts and Sciences.